Treating pain in multiple sclerosis

Bibliography

• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52
   PubMed Web of Science ®Google Scholar
• O'Connor AB, Schwid SR, Herrmann DN, Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 2008;137:96-111
   PubMed Web of Science ®Google Scholar
• Nurmikko TJ, Gupta S, Maclver K. Multiple sclerosis-related central pain disorders. Curr Pain Headache Rep 2010;14:189-95
   PubMed Web of Science ®Google Scholar
• Solaro C, Brichetto G, Amato MP, The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 2004;63:919-21
   PubMed Web of Science ®Google Scholar
• Hadjimichael O, Kerns RD, Rizzo MA, Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain 2007;127:35-41
   PubMed Web of Science ®Google Scholar
• Beiske AG, Pedersen ED, Czujko B, Myhr KM. Pain and sensory complaints in multiple sclerosis. Eur J Neurol 2004;11:479-82
   PubMed Web of Science ®Google Scholar
• Kalia LV, O'Connor PW. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler 2005;11:322-7
   PubMed Web of Science ®Google Scholar
• Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis: prevalence and clinical characteristics. Eur J Pain 2005;9:531-42
   PubMed Web of Science ®Google Scholar
• Svendsen KB, Jensen TS, Overvad K, Pain in patients with multiple sclerosis: a population-based study. Arch Neurol 2003;60:1089-94
   PubMedGoogle Scholar
• Archibald CJ, McGrath PJ, Ritvo PG, Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain 1994;58:89-3
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol 2010;9:1182-99
   PubMed Web of Science ®Google Scholar
• Wissel J, Muller J, Dressnandt J, Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000;20:44-9
   PubMed Web of Science ®Google Scholar
• Agostoni E, Frigerio R, Protti A. Controversies in optic neuritis pain diagnosis. Neurol Sci 2005;26:s75-8
   PubMed Web of Science ®Google Scholar
• Shibasaki H, Kuroiwa Y. Painful tonic seizures in multiple sclerosis. Arch Neurol 1974;30:47-51
   PubMedGoogle Scholar
• Matthews WB. Paroxysmal symptoms in multiple sclerosis. J Neurol Neurosurg Psychiatry 1975;38:617-23
   PubMed Web of Science ®Google Scholar
• Spissu A, Cannas A, Ferrigno P, Anatomic correlates of painful tonic spasms in multiple sclerosis. Mov Disord 1999;14:331-5
   PubMed Web of Science ®Google Scholar
• Treede RD, Jensen TS, Campbell JN, Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5
   PubMed Web of Science ®Google Scholar
• Cruccu G, Gronseth G, Alksne J, AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol 2008;15:1013-28
   PubMed Web of Science ®Google Scholar
• Jensen TS, Rasmussen P, Reske-Nielsen E. Association of trigeminal neuralgia with multiple sclerosis: clinical and pathological features. Acta Neurol Scand 1982;65:182-9
   PubMed Web of Science ®Google Scholar
• Olafson RA, Rushton JG, Sayre GP. Trigeminal neuralgia in a patient with multiple sclerosis: an autopsy report. J Neurosurg 1966;24:755-9
   PubMed Web of Science ®Google Scholar
• Cruccu G, Biasiotta A, Di Rezze S, Trigeminal neuralgia and pain related to multiple sclerosis. Pain 2009;143:186-91
   PubMed Web of Science ®Google Scholar
• Al-Araji AH, Oger J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler 2005;11:398-402
   PubMed Web of Science ®Google Scholar
• Boneschi FM, Colombo B, Annovazzi P, Lifetime and actual prevalence of pain and headache in multiple sclerosis. Mult Scler 2008;14:514-21
   PubMed Web of Science ®Google Scholar
• Osterberg A, Boivie J. Central pain in multiple sclerosis – sensory abnormalities. Eur J Pain 2010;14:104-10
   PubMed Web of Science ®Google Scholar
• IASP. Task force on taxonomy. In: Merskey H, Bogduk N. editors. Classification of chronic pain. 2nd edition. IASP Press; Seattle, WA: 1994
   Google Scholar
• Anderson G, Meyer D, Herrman CE, Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study. J Neurol 2010;257:1917-23
   PubMed Web of Science ®Google Scholar
• Warke K, Al-Smadi J, Baxter D, Efficacy of transcutaneous electrical nerve stimulation (tens) for chronic low-back pain in a multiple sclerosis population: a randomized, placebo-controlled clinical trial. Clin J Pain 2006;22:812-29
   PubMed Web of Science ®Google Scholar
• Deshpande A, Furlan A, Mailis-Gagnon A, Opioids for chronic low-back pain. Cochrane Database Syst Rev 2007;3:CD004959
   PubMed Web of Science ®Google Scholar
• Urquhart DM, Hoving JL, Assendelft WW, Antidepressants for non-specific low back pain. Cochrane Database Syst Rev 2008;1:CD001703
   Google Scholar
• Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003;4:CD001332
   PubMedGoogle Scholar
• Zajicek J, Fox P, Sanders H, Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26
   PubMed Web of Science ®Google Scholar
• Wissel J, Haydn T, Muller J, Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 2006;253:1337-41
   PubMed Web of Science ®Google Scholar
• Sawa GM, Paty DW. The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci 1979;6:351-4
   PubMed Web of Science ®Google Scholar
• Herman RM, D'Luzansky SC, Ippolito R. Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study. Clin J Pain 1992;8:338-45
   PubMed Web of Science ®Google Scholar
• Middel B, Kuipers-Upmeijer H, Bouma J, Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997;63:204-9
   PubMed Web of Science ®Google Scholar
• Dario A, Scamoni C, Bono G, Functional improvement in patients with severe spinal spasticity treated with chronic intrathecal baclofen infusion. Funct Neurol 2001;16:311-15
   PubMed Web of Science ®Google Scholar
• Boviatsis EJ, Kouyialis AT, Korfias S, Sakas DE. Functional outcome of intrathecal baclofen administration for severe spasticity. Clin Neurol Neurosurg 2005;107:289-95
   PubMed Web of Science ®Google Scholar
• Sadiq SA, Poopatana CA. Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity. J Neurol 2007;254:1464-5
   PubMed Web of Science ®Google Scholar
• Mueller ME, Gruenthal M, Olson WL, Olson WH. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil 1997;78:521-4
   PubMed Web of Science ®Google Scholar
• Cutter NC, Scott DD, Johnson JC, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000;81:164-9
   PubMed Web of Science ®Google Scholar
• Hyman N, Barnes M, Bhakta B, Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000;68:707-12
   PubMed Web of Science ®Google Scholar
• Solaro C, Uccelli MM, Guglieri P, Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler 2000;6:192-3
   PubMed Web of Science ®Google Scholar
• Solaro C, Lunardi GL, Capello E, An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology 1998;51:609-11
   PubMed Web of Science ®Google Scholar
• Cianchetti C, Zuddas A, Randazzo AP, Lamotrigine adjunctive therapy in painful phenomena in MS: preliminary observations. Neurology 1999;53:433
   PubMed Web of Science ®Google Scholar
• Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci 1999;162:162-8
   PubMed Web of Science ®Google Scholar
• Restivo DA, Tinazzi M, Patti F, Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology 2003;61:719-20
   PubMed Web of Science ®Google Scholar
• Hooge JP, Redekop WK. Trigeminal neuralgia in multiple sclerosis. Neurology 1995;45:1294-6
   PubMed Web of Science ®Google Scholar
• Lunardi G, Leandri M, Albano C, Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology 1997;48:1714-47
   PubMed Web of Science ®Google Scholar
• Leandri M, Lundardi G, Inglese M, Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol 2000;247:556-68
   PubMed Web of Science ®Google Scholar
• Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998;51:611-14
   PubMed Web of Science ®Google Scholar
• Solaro C, Messmer Uccelli M, Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol 2000;44:45-8
   PubMed Web of Science ®Google Scholar
• Zvartau-Hind M, Din MU, Gilani A, Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology 2000;55:1587-8
   PubMed Web of Science ®Google Scholar
• Reder AT, Arnason BG. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology 1995;45:1097-100
   PubMed Web of Science ®Google Scholar
• DMKG study group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol 2003;250:542-5
   PubMed Web of Science ®Google Scholar
• Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbamazepine (tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1966;29:265-7
   PubMed Web of Science ®Google Scholar
• Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Arch Neurol 1968;19:129-36
   PubMed Web of Science ®Google Scholar
• Nicol CF. A four year double blind study of tegretol in facial pain. Headache 1969;9:54-7
   PubMedGoogle Scholar
• Rockcliff BW, Davis EH. Controlled sequential trials of carbamazepine in trigeminal neuralgia. Arch Neurol 1996;15:129-36
   Google Scholar
• Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 2002;6:61-8
   PubMed Web of Science ®Google Scholar
• Beydoun A. Safety and efficacy of oxcarbazepine: results of randomized, double-blind trials. Pharmacotherapy 2000;20:152-8S
   PubMed Web of Science ®Google Scholar
• Liebel JT, Menger N, Langohr H. Oxcarbazepine in der Behandlung der Trigeminusneuralgie. Nervenheilkunde 2001;20:461-5
   Google Scholar
• Houtchens MK, Richert JR, Sami A, Rose JW. Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler 1997;3:250-3
   PubMed Web of Science ®Google Scholar
• Samkoff LM, Daras M, Tuchman AJ, Koppel BS. Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin. Neurology 1997;49:304-5
   PubMed Web of Science ®Google Scholar
• McCleane G. Lamotrigine can reduce neurogenic pain associated with multiple sclerosis. Clin J Pain 1998;14:269-70
   PubMed Web of Science ®Google Scholar
• Breuer B, Pappagallo M, Knotkova H, A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther 2007;29:2022-30
   PubMed Web of Science ®Google Scholar
• Silver M, Blum D, Grainger J, Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage 2007;34:446-54
   PubMed Web of Science ®Google Scholar
• Rossi S, Mataluni G, Codeca C, Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. Eur J Neurol 2009;16:360-6
   PubMed Web of Science ®Google Scholar
• Clifford DB, Trotter JL. Pain in multiple sclerosis. Arch Neurol 1984;41:1270-2
   PubMedGoogle Scholar
• Kalman S, Osterberg A, Sorensen J, Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i.v. morphine. Eur J Pain 2002;6:69-80
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Twilling L, Davies PS, Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;348:1223-32
   PubMed Web of Science ®Google Scholar
• Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol 2010;68:145-50
   PubMed Web of Science ®Google Scholar
• Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 2010;16:964-9
   PubMed Web of Science ®Google Scholar
• Wade DT, Robson P, House H, A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17:21-9
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela P, Robson P, Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41
   PubMed Web of Science ®Google Scholar
• Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomized double blind placebo controlled crossover trial. BMJ 2004;329:253-61
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Friede T, Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-19
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta-9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007;29:2068-79
   PubMed Web of Science ®Google Scholar
• Zajicek JP, Apostu VI. Role of cannabinoids in multiple sclerosis. CNS Drugs 2011;25:187-201
   PubMed Web of Science ®Google Scholar
• Fox A, Kesingland A, Gentry C, The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001;92:91-100
   PubMed Web of Science ®Google Scholar
• Richardson JD. Cannabinoids modulate pain by multiple mechanisms of action. Pain 2000;1:2-14
   Web of Science ®Google Scholar
• Hohmann AG, Tsou K, Walker JM. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2. Neurosci Lett 1998;257:119-22
   PubMed Web of Science ®Google Scholar
• Shen M, Piser TM, Seybold VS, Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996;16:4322-34
   PubMed Web of Science ®Google Scholar
• Pugh G Jr, Abood ME, Welch SP. Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta 9-THC in the spinal cord. Brain Res 1995;689:157-8
   PubMed Web of Science ®Google Scholar
• Ware MA, St Arnaud-Trempe E. The abuse potential of the synthetic cannabinoid nabilone. Addiction 2010;105:494-503
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela PM, House H, Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12:639-45
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O'Connor AB, Audette J, Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3-14
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88
   PubMed Web of Science ®Google Scholar
• Cruccu G. Treatment of painful neuropathy. Curr Opin Neurol 2007;20:531-5
   PubMed Web of Science ®Google Scholar
• Siddall PJ, Cousins MJ, Otte A, Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006;67:1792-800
   PubMed Web of Science ®Google Scholar
• Vranken JH, Dijkgraaf MG, Kruis MR, Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 2008;136:150-7
   PubMed Web of Science ®Google Scholar
• Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008;31:1448-54
   PubMed Web of Science ®Google Scholar
• Moore RA, Straube S, Wiffen PJ, Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009;3:CD007076
   PubMed Web of Science ®Google Scholar
• Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998;51:1166-71
   PubMed Web of Science ®Google Scholar
• Ray WA, Meredith S, Thapa PB, Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004;75:234-41
   PubMed Web of Science ®Google Scholar
• Sir A, D'Souza RF, Uguz S, Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 2005;66:1312-20
   PubMed Web of Science ®Google Scholar
• Kajdasz DK, Iyengar S, Desaiah D, Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 2007;29:2536-46
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Panjwani ZD, Nguyen HT, The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 2008;4:281-5
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Farrar JT, Backonja MM, Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain 2007;23:287-99
   PubMed Web of Science ®Google Scholar
• Pertovaara A, Almeida A. Chapter 13. Descending inhibitory systems. Handb Clin Neurol 2006;81:179-92
   PubMedGoogle Scholar
• Cruccu G, Truini A. Sensory profiles: a new strategy for selecting patients in treatment trials for neuropathic pain. Pain 2009;146:5-6
   PubMed Web of Science ®Google Scholar
• Truini A, Biasiotta A, La Cesa S, Mechanisms of pain in distal symmetric polyneuropathy: a combined clinical and neurophysiological study. Pain 2010;150:516-21
   PubMed Web of Science ®Google Scholar